Skip to content

Current ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.4×+0.1×
Amgen logo
AmgenAMGN
1.3×+0.1×
Tango Therapeutics logo
Tango TherapeuticsTNGX
27.4×+21.1×
Arcus Biosciences logo
Arcus BiosciencesRCUS
-1.3×
Erasca, Inc. logo
Erasca, Inc.ERAS
9.5×-2.8×
Immunome logo
ImmunomeIMNM
21.7×+11.2×

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.36B+104%
Enterprise value$3.23B+110%
P/S14.5×+9.9×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×

Where this comes from

Calculated from IDEAYA Biosciences, Inc.’s reported figures.

Based on the most recent quarter.

The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s current ratio?
IDEAYA Biosciences, Inc. (IDYA) reported current ratio of 10.7× in Q1 2026.
How has IDEAYA Biosciences, Inc.'s current ratio changed year-over-year?
IDEAYA Biosciences, Inc.'s current ratio decreased by 22.9% year-over-year, from 13.9× to 10.7×.
What is the long-term trend for IDEAYA Biosciences, Inc.'s current ratio?
Over 5 years (2020 to 2025), IDEAYA Biosciences, Inc.'s current ratio has grown at a 8.7% compound annual growth rate (CAGR), from 7.5× to 11.3×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.